PT ? . times institutional ULN
Coagulation: PT >  seconds more than ULN or INR > .
PT/INR ? ULN within  days of randomization. Patients receiving therapeutic anti-coagulants are not eligible.
For participants who have not received prior neoadjuvant chemotherapy: tumor stage of pT-a or pN+ (pT- or pN+ for participants with upper urinary tract UC) and M
Has received prior treatment with PT or another HIF-? inhibitor
Intermediate-high risk RCC: pT, Grade  or sarcomatoid, N, M; pT, Any Grade, N, M
High risk RCC: pT, Any Grade N, M; pT, Any stage, Any Grade, N+, M
Patient (Pt) may be excluded if, in the opinion of the principal investigator (PI) and investigator team, the pt is not capable of being compliant
Pt may be excluded if, in the opinion of the principal investigator (PI) and investigator team, the pt is not capable of being compliant
IMMUNE RECONSTITUTION STUDY ONLY: Received haploidentical BMT with the current standard of two days of PT-CY (and no PT-BEN)
Patient (Pt) may be excluded if, in the opinion of the principal investigator (PI) and investigator team, the pt is not capable of being compliant
PT ?. ULN
PT <. ULN
One of the following pathologic T-classifications: pT or pT\r\n* Patients with positive surgical margins are eligible
pT, G any, N; or, pT, G any, N; or, pT any, G any, N or M)
Normal PT or INR and aPTT
PT/aPIT ? . x ULN
PT/INR and aPTT ? . ULN.
PT or aPTT < . times the ULN
Patients with pT or pT disease
